It remains unclear why some tumor types do not respond to immune checkpoint blockade (ICB) therapies. Researchers at KU Leuven investigated CD8+ T cell functionality across different tumor types to determine what drives the hypofunctional T cell state in ICB-nonresponsive cancers. They used single-cell proteomics to uncover the mechanisms behind CD8+ T cell dysfunction in glioblastoma.
Download this research summary from Bruker Cellular Analysis to learn how researchers used the IsoCode® Single-Cell Secretome platform to define new immune cell populations in low antigenic tumors and pave the way for new immunotherapies.
